Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Yun Jin, Yihe Dai, Ou Qiao, Pingping Hu, Jiang Han
AIM: To understand the regulatory roles of miR-1972 and GZMH in hepatocellular carcinoma (HCC) and explore their potential as therapeutic biomarkers. METHODS: In vitro verification of the regulation of malignant cell behavior by differential expression of miR-1972 in HCC cells. The GSE113996 dataset was studied using weighted gene co-expression network analysis (WGCNA) and differential expressed genes respectively to identify the key prognostic gene GZMH and assess the effect of its differential expression on the prognosis of the patient...
April 18, 2024: Journal of Pharmacy and Pharmacology
#2
JOURNAL ARTICLE
Kayleigh Smith, Dan Beach, Roger Silva, Gyorffy Balazs, Francesca Salani, Francesco Crea
Robust prognostic and predictive factors for hepatocellular carcinoma, a leading cause of cancer-related deaths worldwide, have not yet been identified. Previous studies have identified potential HCC determinants such as genetic mutations, epigenetic alterations, and pathway dysregulation. However, the clinical significance of these molecular alterations remains elusive. MicroRNAs are major regulators of protein expression. MiRNA functions are frequently altered in cancer. In this study, we aimed to explore the prognostic value of differentially expressed miRNAs in HCC, to elucidate their associated pathways and their impact on treatment response...
2024: PloS One
#3
JOURNAL ARTICLE
Lixia Liu, Meng Zhang, Naipeng Cui, Wenwen Liu, Guixin Di, Yanan Wang, Xin Xi, Hao Li, Zhou Shen, Miaomiao Gu, Zichao Wang, Shan Jiang, Bin Liu
BACKGROUND: Liver hepatocellular carcinoma (LIHC) is a prevalent form of primary liver cancer. Research has demonstrated the contribution of tumor stem cells in facilitating tumor recurrence, metastasis, and treatment resistance. Despite this, there remains a lack of established cancer stem cells (CSCs)-associated genes signatures for effectively predicting the prognosis and guiding the treatment strategies for patients diagnosed with LIHC. METHODS: The single-cell RNA sequencing (scRNA-seq) and bulk RNA transcriptome data were obtained based on public datasets and computerized firstly using CytoTRACE package and One Class Linear Regression (OCLR) algorithm to evaluate stemness level, respectively...
2024: PloS One
#4
JOURNAL ARTICLE
Zhefeng Huang, Anthony L Gunderman, Samuel E Wilcox, Saikat Sengupta, Jay Shah, Aiming Lu, David Woodrum, Yue Chen
MR-guided microwave ablation (MWA) has proven effective in treating hepatocellular carcinoma (HCC) with small-sized tumors, but the state-of-the-art technique suffers from sub-optimal workflow due to the limited accuracy provided by the manual needle insertions. This paper presents a compact body-mounted MR-conditional robot that can operate in closed-bore MR scanners for accurate needle guidance. The robotic platform consists of two stacked Cartesian XY stages, each with two degrees of freedom, that facilitate needle insertion pose control...
April 18, 2024: Annals of Biomedical Engineering
#5
EDITORIAL
Maurizio Bonacini
No abstract text is available yet for this article.
May 2024: Liver International: Official Journal of the International Association for the Study of the Liver
#6
REVIEW
Zha Peng, Zhuang-Rong Zhu, Cheng-Yi He, Hai Huang
BACKGROUND: The indication of laparoscopic liver resection (LLR) for treating large hepatocellular carcinoma (HCC) is controversial. In this study, we compared the short-term and long-term outcomes of LLR and open liver resection (OLR) for large HCC. MATERIAL AND METHODS: We searched eligible articles about LLR versus OLR for large HCC in PubMed, Cochrane Library, and EMBASE and performed a meta-analysis. RESULTS: Eight publications involving 1,338 patients were included...
April 18, 2024: Minimally Invasive Therapy & Allied Technologies: MITAT
#7
REVIEW
Meng Huang, Zhiwen Zhao, Lihua Yang
BACKGROUND: Recently, increasing data have suggested that the lncRNA small nucleolar RNA host genes (SNHGs) were aberrantly expressed in hepatocellular carcinoma (HCC), but the association between the prognosis of HCC and their expression remained unclear. The purpose of this meta-analysis was to determine the prognostic significance of lncRNA SNHGs in HCC. METHODS: We systematically searched Embase, Web of Science, PubMed, and Cochrane Library for eligible articles published up to February 2024...
April 2024: Cancer Medicine
#8
JOURNAL ARTICLE
Xiaofeng Dong, Mengjie Zou, Chunxing Li, Honglin Luo, Shaoliang Zhu, Zheng Gong
Increasing evidence has suggested a strong association of hepatocellular carcinoma (HCC) susceptibility and Gln223Arg (rs1137101) and Lys109Arg (rs1137100) polymorphisms in leptin receptor (LEPR) genes. To provide a quantitative assessment for such correlation, we reviewed all related systems and conducted meta-analysis for case and control researches. A literature search of Web of Science, EMBASE, PubMed, Scopus as well as China National Knowledge Infrastructure databases was collected. 95% confidence intervals (95% CIs) together with odds ratios (ORs) were calculated...
April 18, 2024: Environmental Toxicology
#9
REVIEW
Ali Tavakoli Pirzaman, Ali Alishah, Bahareh Babajani, Pouyan Ebrahimi, Seyyed Ali Sheikhi, Farhad Moosaei, Amirhossein Salarfar, Shahrbanoo Doostmohamadian, Sohrab Kazemi
Globally, hepatic cancer ranks fourth in terms of cancer-related mortality and is the sixth most frequent kind of cancer. Around 80% of liver cancers are hepatocellular carcinomas (HCC), which are the leading cause of cancer death. It is well known that HCC may develop resistance to the available chemotherapy treatments very fast. One of the biggest obstacles in providing cancer patients with appropriate care is drug resistance. According to reports, more than 90% of cancer-specific fatalities are caused by treatment resistance...
2024: Technology in Cancer Research & Treatment
#10
REVIEW
Wnt/β-Catenin signaling pathway in hepatocellular carcinoma: pathogenic role and therapeutic target.
Zekun Zhao, Tenglu Cui, Fengxian Wei, Zhiming Zhou, Yuan Sun, Chaofeng Gao, Xiaodong Xu, Huihan Zhang
Hepatocellular carcinoma (HCC) is the most common primary malignant liver tumor and one of the leading causes of cancer-related deaths worldwide. The Wnt/β-Catenin signaling pathway is a highly conserved pathway involved in several biological processes, including the improper regulation that leads to the tumorigenesis and progression of cancer. New studies have found that abnormal activation of the Wnt/β-Catenin signaling pathway is a major cause of HCC tumorigenesis, progression, and resistance to therapy...
2024: Frontiers in Oncology
#11
Soichiro Okamoto, Yusuke Matsui, Shoichi Komoto, Takao Hiraki
We report the rare case of an 80-year-old man with hepatocellular carcinoma that ruptured in the gallbladder, causing a cystic artery pseudoaneurysm and hemobilia. Emergency transarterial embolization (TAE) successfully controlled the bleeding without causing ischemic cholecystitis. Cone-beam computed tomography angiography was useful in identifying the bleeding branch of the selectively embolized cystic artery. Although the patient had poor liver function (Child-Pugh class C) before TAE, it remarkably improved after embolization due to the resolution of coagulopathy and obstructive jaundice caused by hemobilia...
March 2024: Curēus
#12
REVIEW
Pınar Korkmaz, Ali Asan, Faruk Karakeçili, Süda Tekin, Neşe Demirtürk
Hepatitis B virus (HBV) infection is the leading cause of chronic liver disease worldwide. HBV-infected patients are at a lifetime risk of developing liver cirrhosis and hepatocellular carcinoma (HCC). Today, pegylated interferon (Peg-IFN) and nucleos(t)ide analogs (NAs) are used in the treatment of patients with chronic hepatitis B (CHB). Both treatment options have limitations. Despite effective viral suppression, NAs have little effect on covalently closed circular DNA (cccDNA), the stable episomal form of the HBV genome in hepatocytes...
December 2023: Infect Dis Clin Microbiol
#13
Azlann Arnett, David A Siegel, Shifan Dai, Trevor D Thompson, Jennifer Foster, Erika J di Pierro, Behnoosh Momin, Philip J Lupo, Andras Heczey
IMPORTANCE: Hepatocellular carcinoma accounts for approximately 80% of liver neoplasms. Globally, hepatocellular carcinoma ranks as the third most lethal cancer, with the number of deaths expected to further increase by 2040. In adults, disparities in incidence and survival are well described while pediatric epidemiology is not well characterized. OBJECTIVE: To describe incidence and survival for pediatric (ages 0-19 years) hepatocellular carcinoma cases and compare these measures to adults (ages ≥20 years) diagnosed with hepatocellular carcinoma...
April 5, 2024: medRxiv
#14
JOURNAL ARTICLE
Sulaiman S Alhudaithi, Mohd Abul Kalam, Lama Binobaid, Raisuddin Ali, Mohammed M Almutairi, Wajhul Qamar, Hessa Bin Hithlayn, Atheer Almutairi, Abdullah K Alshememry
Hepatocellular carcinoma (HCC) exhibits high mortality rates in the advanced stage (>90 %). Sorafenib (SORA) is a targeted therapy approved for the treatment of advanced HCC; however, the reported response rate to such a therapeutic is suboptimal (<3%). Piperine (PIP) is an alkaloid demonstrated to exert a direct tumoricidal activity in HCC and improve the pharmacokinetic profiles of anticancer drugs including SORA. In this study, we developed a strategy to improve efficacy outcomes in HCC using PIP as an add-on treatment to support the first-line therapy SORA using biodegradable Poly (D, L-Lactide-co-glycolide, PLGA) nanoparticles (NPs)...
May 2024: Saudi Pharmaceutical Journal: SPJ: the Official Publication of the Saudi Pharmaceutical Society
#15
JOURNAL ARTICLE
Zhixiong Su, Yufang He, Lijie You, Guifeng Zhang, Jingbo Chen, Zhenhua Liu
BACKGROUND: Hyaluronan-mediated motility receptor (HMMR) is overexpressed in multiple carcinomas and influences the development and treatment of several cancers. However, its role in hepatocellular carcinoma (HCC) remains unclear. METHODS: The "limma" and "GSVA" packages in R were used to perform differential expression analysis and to assess the activity of signalling pathways, respectively. InferCNV was used to infer copy number variation (CNV) for each hepatocyte and "CellChat" was used to analyse intercellular communication networks...
2024: Frontiers in Immunology
#16
JOURNAL ARTICLE
Shreya Shalimar Datta Gupta, Shamim A Shamim, Shivanand Gamanagatti, Priyanka Gupta, Maroof A Khan, Madhav B Mallia, Viju Chirayil, Ashutosh Dash, Chandrasekhar Bal
OBJECTIVE: Hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT) have limited therapeutic options, Re-188 lipiodol transarterial therapy being one of them. We aimed to assess the safety and efficacy of Re-188 lipiodol exclusively in HCC with PVT as well as to compare two chelating agents for the synthesis of Re-188 lipiodol: novel bis-(diethyldithiocarbamato) nitrido (N-DEDC) with existing acetylated 4-hexadecyl 1-2,9,9-tetramethyl-4,7-diaza-1,10-decanethiol [(A)HDD]. METHODS: Patients with radiological diagnosis of HCC with PVT having Eastern Cooperative Oncology Group (ECOG) performance status ≤2 and Child Pugh score (PS) A or B were recruited...
April 5, 2024: Nuclear Medicine Communications
#17
JOURNAL ARTICLE
Shanshan Xu, Xiao-Hang Wu, Lin Wu, Jia-Min Zhai, Shi-Jun Li, Yichuan Kou, Wei Peng, Qing-Na Zheng, Jing-Hua Tian, Yue-Jiao Zhang, Jian-Feng Li
Hepatitis B virus (HBV) is a major cause of liver cirrhosis and hepatocellular carcinoma, with HBV surface antigen (HBsAg) being a crucial marker in the clinical detection of HBV. Due to the significant harm and ease of transmission associated with HBV, HBsAg testing has become an essential part of preoperative assessments, particularly for emergency surgeries where healthcare professionals face exposure risks. Therefore, a timely and accurate detection method for HBsAg is urgently needed. In this study, a surface-enhanced Raman scattering (SERS) sensor with a sandwich structure was developed for HBsAg detection...
April 18, 2024: Analytical Chemistry
#18
JOURNAL ARTICLE
Li Zhang, Qian Liu, Yongcan Guo, Luyao Tian, Kena Chen, Dan Bai, Hongyan Yu, Xiaole Han, Wang Luo, Tong Feng, Shixiong Deng, Guoming Xie
Although gene expression signatures offer tremendous potential in diseases diagnostic and prognostic, but massive gene expression signatures caused challenges for experimental detection and computational analysis in clinical setting. Here, we introduce a universal DNA-based molecular classifier for profiling gene expression signatures and generating immediate diagnostic outcomes. The molecular classifier begins with feature transformation, a modular and programmable strategy was used to capture relative relationships of low-concentration RNAs and convert them to general coding inputs...
April 17, 2024: Journal of Nanobiotechnology
#19
JOURNAL ARTICLE
Jonas Ghouse, Gardar Sveinbjörnsson, Marijana Vujkovic, Anne-Sofie Seidelin, Helene Gellert-Kristensen, Gustav Ahlberg, Vinicius Tragante, Søren A Rand, Joseph Brancale, Silvia Vilarinho, Pia Rengtved Lundegaard, Erik Sørensen, Christian Erikstrup, Mie Topholm Bruun, Bitten Aagaard Jensen, Søren Brunak, Karina Banasik, Henrik Ullum, Niek Verweij, Luca Lotta, Aris Baras, Tooraj Mirshahi, David J Carey, David E Kaplan, Julie Lynch, Timothy Morgan, Tae-Hwi Schwantes-An, Daniel R Dochtermann, Saiju Pyarajan, Philip S Tsao, Triin Laisk, Reedik Mägi, Julia Kozlitina, Anne Tybjærg-Hansen, David Jones, Kirk U Knowlton, Lincoln Nadauld, Egil Ferkingstad, Einar S Björnsson, Magnus O Ulfarsson, Árni Sturluson, Patrick Sulem, Ole B Pedersen, Sisse R Ostrowski, Daniel F Gudbjartsson, Kari Stefansson, Morten Salling Olesen, Kyong-Mi Chang, Hilma Holm, Henning Bundgaard, Stefan Stender
We report a multi-ancestry genome-wide association study on liver cirrhosis and its associated endophenotypes, alanine aminotransferase (ALT) and γ-glutamyl transferase. Using data from 12 cohorts, including 18,265 cases with cirrhosis, 1,782,047 controls, up to 1 million individuals with liver function tests and a validation cohort of 21,689 cases and 617,729 controls, we identify and validate 14 risk associations for cirrhosis. Many variants are located near genes involved in hepatic lipid metabolism...
April 17, 2024: Nature Genetics
#20
JOURNAL ARTICLE
Danuta Szkutnik-Fiedler, Edyta Szałek, Filip Otto, Andrzej Czyrski, Marta Karaźniewicz-Łada, Anna Wolc, Edmund Grześkowiak, Konrad Lewandowski, Agnieszka Karbownik
BACKGROUND: Regorafenib is used in the treatment of colorectal cancer and hepatocellular carcinoma. Due to the co-morbidity of hyperlipidemia in these conditions, statins, including atorvastatin, are used as potential adjuvant therapy agents. Both regorafenib and atorvastatin are metabolized by CYP3A4. In addition, atorvastatin is a P-gp and BCRP substrate, whereas regorafenib and its active metabolites M-2 and M-5 are inhibitors of these transporters. Hence, the concomitant use of both drugs may increase the risk of a clinically significant drug-drug interaction...
April 18, 2024: Pharmacological Reports: PR
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
